Illinois Municipal Retirement Fund Has $63.72 Million Stake in Johnson & Johnson $JNJ

Illinois Municipal Retirement Fund cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 343,627 shares of the company’s stock after selling 10,748 shares during the quarter. Johnson & Johnson comprises 0.8% of Illinois Municipal Retirement Fund’s portfolio, making the stock its 11th biggest holding. Illinois Municipal Retirement Fund’s holdings in Johnson & Johnson were worth $63,715,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in JNJ. ICW Investment Advisors LLC raised its position in shares of Johnson & Johnson by 5.3% in the third quarter. ICW Investment Advisors LLC now owns 17,914 shares of the company’s stock valued at $3,322,000 after purchasing an additional 902 shares during the period. Wedbush Securities Inc. raised its holdings in Johnson & Johnson by 12.3% in the 3rd quarter. Wedbush Securities Inc. now owns 60,770 shares of the company’s stock valued at $11,268,000 after acquiring an additional 6,638 shares during the period. Varma Mutual Pension Insurance Co lifted its position in Johnson & Johnson by 8.9% during the third quarter. Varma Mutual Pension Insurance Co now owns 378,256 shares of the company’s stock worth $70,136,000 after acquiring an additional 30,900 shares during the last quarter. Elmwood Wealth Management Inc. boosted its holdings in shares of Johnson & Johnson by 7.1% during the third quarter. Elmwood Wealth Management Inc. now owns 5,670 shares of the company’s stock worth $1,051,000 after acquiring an additional 374 shares during the period. Finally, Beacon Bridge Wealth Partners LLC grew its holdings in Johnson & Johnson by 5.8% in the 3rd quarter. Beacon Bridge Wealth Partners LLC now owns 1,478 shares of the company’s stock valued at $274,000 after buying an additional 81 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $240.97 on Thursday. The company’s 50 day moving average price is $215.57 and its two-hundred day moving average price is $195.51. The firm has a market capitalization of $580.56 billion, a P/E ratio of 21.81, a P/E/G ratio of 2.31 and a beta of 0.35. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $241.26. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The company had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%. On average, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. Johnson & Johnson’s dividend payout ratio is currently 47.06%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on JNJ. Daiwa Securities Group lifted their target price on Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a report on Thursday, January 29th. Raymond James Financial lifted their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. Wells Fargo & Company increased their target price on shares of Johnson & Johnson from $230.00 to $240.00 and gave the stock an “overweight” rating in a research report on Thursday, January 22nd. Stifel Nicolaus lifted their price target on shares of Johnson & Johnson from $205.00 to $220.00 and gave the company a “hold” rating in a research report on Thursday, January 22nd. Finally, Johnson Rice set a $190.00 price target on Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $233.73.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.